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marily for metastatic or recurrent disease. To our knowledge, there are
no reports on the use of an mTOR inhibitor as adjuvant therapy in the
setting of a malignant uterine PEComa. Small studies demonstrating
tumor shrinkage and clinical response to mTOR inhibitors merit addi-
tional investigation (Gennatas et al., 2012; Italiano et al., 2010;
Wagner et al., 2010). We present a case of a malignant uterine PEComa
in a young, nulliparous patient treated with adjuvant chemotherapy
followed by surgical excision.Introduction
Perivascular epithelioid cell tumors (PEComas) are a family of rare,
poorly deﬁned mesenchymal tumors of uncertain malignant potential
found in various locations throughout the body. They are composed of
epithelioid and spindle cells, have a perivascular distribution, and
display immunoreactivity for melanocytic markers, most frequently
HMB-45, and smooth muscle markers (actin and/or desmin) (Fadore,
2008; Folpe et al., 2005). A review by Bleeker et al. of all 234 published
cases of PEComas identiﬁed the uterus as the most common site of ori-
gin comprising 20% of caseswhile the lung is themost common location
for metastatic disease (Bleeker et al., 2012).
Treatment for PEComashas historically involved excisional biopsy or
surgical resection. Neoadjuvant and adjuvant therapies with chemo-
therapy and/or radiation have also been described in a small number
of cases with mixed results. The majority of chemotherapy regimens
have typically used similar regimens for soft tissue sarcomas, utilizing
an anthracycline backbone, however, no uniform regimen has been pro-
posed or utilized (Folpe, 2002). Recently a class ofmedication that inter-
feres with the mammalian target of rapamycin (mTOR), called mTOR
inhibitors, has emerged as a promising therapy with the discovery
that activation of the mTOR-signaling pathway occurs in PEComas.Oncology,Walter Reed National
D 20814.
-NC-ND license. Case
A healthy, 19-year-old nulligravida Caucasian woman presented to
her primary provider with complaints of abdominal pain, vomiting,
and dizziness. Her medical history was unremarkable to include no
family history of cancer or tuberous sclerosis. Imaging studies revealed
a large, hypervascular mass in the posterior cul de sac measuring ap-
proximately 8 cm in diameter. The patient subsequently underwent a
diagnostic laparoscopy, whichwas converted to an exploratory laparot-
omy for removal of the mass. The large posterior uterine mass was
resected at its base, however, resulted in a blood loss of 1100 cm3 sec-
ondary to its hypervascularity. Additional tumor located on the anterior
uterine wall was not resected given concern for additional blood loss,
and possible need for emergent hysterectomy to control bleeding. The
ﬁnal tissue pathology returned as aggressive/malignant perivascular ep-
ithelioid tumor (PEComa) which was conﬁrmed by outside pathologic
consultation. The tissue characteristics included epithelioid and spindle
cells with clear and granular cytoplasm, and prominent vasculature
around which the tumor cells were arranged (Figs. 1 & 2). Nuclear
atypia was identiﬁed, as well as mitotic activity of at least 1 mitosis/50
high-powered ﬁelds (HPF). Tissue stains were positive for HMB-45,
smooth muscle actin, and desmin, and negative for S100 and melan-A.
Treatment typically involves surgical excision, which may have re-
quired a hysterectomy in this nulliparous patient who desired future
fertility. Given the inability to remove the entire tumor during the initial
surgery, she was considered suboptimally debulked. With her young
age and future fertility desires, conservativemanagementwith adjuvant
temsirolimus, an mTOR inhibitor, followed by interval surgical excision
of remaining tumor was chosen after discussing available management
options. Temsirolimus is currently approved by the Food and Drug Ad-
ministration for advanced renal cell carcinoma and therefore, was
used off-label in this patient. The patient was thoroughly counseled re-
garding the off-label use of Temsirolimus for her as well as the risks of
Fig. 1. Neoplastic epithelioid to spindled cells with a staghorn vessel in the background.
Fig. 3. Neoplastic cell with granular cytoplasm and intranuclear pseudoinclusion.
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4) being rash, dyspnea, pain, and asthenia (Kwitkowski et al., 2010).
The patient received 12 cycles of temsirolimus 25 mg IV weekly. A
pelvic magnetic resonance image (MRI) performed following adjuvant
therapy demonstrated interval reduction in the size of the uterine
mass by approximately 65% compared to prior imaging, indicating a
positive therapeutic response. Following completion of the adjuvant
temsirolimus, the patient underwent laparotomy with resection of the
remaining uterine mass, and various peritoneal and omental biopsies.
There was no evidence of metastatic spread on surgical or pathologic
evaluation. The patient's postoperative course was uncomplicated.
Follow-up at ﬁfteen months post-treatment was encouraging with no
evidence of disease. Ongoing surveillance will be necessary to evaluate
progression of disease in this patient treated with mTOR inhibitor ther-
apy for malignant PEComa.Discussion
Uterine perivascular epithelioid cell tumors are exceedingly rare
mesenchymal tumors. The term “PEComa” was ﬁrst introduced in
1996 by Zamboni and colleagues and in 2002 theWorld Health Organi-
zation (WHO) ﬁrst recognized the perivascular epithelioid cell tumors
as a distinct clinicopathologic entity (Fadore, 2008; Folpe, 2002). How-
ever, the concept of a family of perivascular epithelioid cell tumors dates
back prior to 1996 when histologic and immunohistochemical associa-
tions were noticed between various soft tissue tumors. Other mesen-
chymal neoplasms that comprise the family of perivascular epithelioidFig. 2. Epithelioid and spindle cells with clear to eosinophilic, granular cytoplasm.cell tumors include lymphangioleiomyomatosis (LAM), clear cell sugar
tumor of the lung (CCST), and angiomyolipoma (AML) of the kidney,
among other rare tumors characterized by perivascular epithelioid
cells (Fadore, 2008; Folpe et al., 2005; Yamamoto et al., 2010).
The morphologic features of PEComas include epithelioid and/or
spindled cells with clear to eosinophilic cytoplasm and a varying degree
of growth around vessels as well as positive immunoreactivity for
melanocytic and smooth muscle tumor markers. Perivascular epitheli-
oid cell tumors may be confused with both smooth muscle tumors
and carcinomas. Morphologic evaluation will demonstrate clear or
lightly eosinophilic cytoplasm and round nuclei (Fig. 3) in PEComas in
contrast to the diffuse cytoplasmic eosinophilia and cigar-shaped nuclei
found in smoothmuscle tumors. However, immunohistochemistrymay
be more useful in distinguishing a PEComa from a carcinoma by the
presence of positive melanocytic marker expression found in PEComas,
unlike carcinomas (Fadore, 2008; Folpe et al., 2005). The tumors also
have a female predilection with a female-to-male ratio ranging from
4:1 to 9:1 which persists when gender-speciﬁc locations are excluded
(Folpe et al., 2005; Bleeker et al., 2012).
A wide variety of treatment modalities have been utilized for
PEComas. No treatment approach has been shown to be consistently
effective, however, no randomized trials are available due to the rarity
of the disease. Traditionally, therapy has involved surgical excision of
the primary tumor. Neoadjuvant and adjuvant therapies have utilized
chemotherapy, radiotherapy, chemoradiation, immunotherapy with
interferon-alpha and hormonal therapy with tamoxifen. Chemothera-
peutic regimens have included ifosfamide, doxorubicin, vincristine,
cyclophosphamide, and platinum agents, among others (Bleeker et al.,
2012). An association between tuberous sclerosis complex (TSC) and
AML and LAMwaspreviously establishedwhen itwas observed that pa-
tients with tuberous sclerosis have a higher rate of AML and LAM com-
pared to the general population. Tuberous sclerosis is an autosomal
dominant disease caused bymutations in the TSC1 or TSC2 genes. A ge-
netic association was demonstrated between TSC and the PEComa fam-
ily with the discovery of germline mutations of the TSC locus in TSC-
associated AML and LAM. Interest in the use of mTOR inhibitors for
treatment of PEComas arose when further investigation revealed that
TSC1 and TSC2 genes regulate cell proliferation via the mTOR pathway.
Loss of the TSC locus, therefore, results in impaired activation of the
mTOR complex and unregulated cellular proliferation (Folpe et al.,
2005; Bleeker et al., 2012; Wagner et al., 2010). Treatment of PEComas
with mTOR inhibitors, such as temsirolimus, has been reported in the
literature, however, not for a malignant uterine PEComa (Gennatas
et al., 2012; Italiano et al., 2010). The discovery that PEComas share ac-
tivation of themTOR pathway has presented the opportunity to investi-
gate the use of mTOR inhibitors as a new treatment modality for these
tumors.
16 K. Bunch, J. Sunde / Gynecologic Oncology Reports 8 (2014) 14–16The majority of PEComas are benign, however, a subset of these
tumors have demonstrated malignant, invasive behavior with either
local recurrences or distant metastases. In 2005, Folpe et al. proposed a
classiﬁcation scheme for categorizing the disease into three subgroups,
“benign, malignant, or tumors of uncertain malignant potential.” Tumors
were classiﬁed as malignant if they demonstrated two or more of the fol-
lowing features: tumor size N5 cm, high nuclear grade, necrosis, mitotic
activity N1/50 HPF, and inﬁltrative growth pattern/vascular invasion. Tu-
mors were classiﬁed as benign if the above features were absent, while
those tumors N5 cm without the other features noted in the malignant
category were labeled uncertain malignant potential (Folpe et al., 2005).
Further analysis by Bleeker et al. demonstrated that tumor size N5 cm
and a mitotic rate N1/50 HPF are the best predictors of tumor recurrence
(Bleeker et al., 2012). In the case described, the tumor met the proposed
criteria for amalignant tumor, and thus, higher potential for tumor recur-
rence, based on size, mitotic activity, and nuclear atypia.
Despite better characterization of PEComas over the last few decades,
they remain a heterogeneous group of tumors with variable biologic
behavior, which makes it difﬁcult to deﬁne prognosis and provide treat-
ment recommendations. Increasing recognition of this family of tumors
will likely lead to improved characterization, and subsequently, manage-
ment and treatment regimens. To date, there is no consensus regarding
treatment that has shown consistent efﬁcacy. Targeted therapy, such as
with mTOR inhibitors, shows promise as a new treatment modality for
this family of rare tumors, particularly for uterine PEComas, which has
not been reported previously (Bleeker et al., 2012). As demonstrated in
our patient who had multiple high-risk criteria on pathologic evaluation,
the use of mTOR inhibitors may provide the best medical treatment cur-
rently available, as well as a fertility-sparing treatment option for young,
female patients desiring future fertility.Conﬂict of interest statement
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